Skip Navigation

A Phase IB/II Study of Onvansertib PCM-075 in Combination with Either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia AML

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03303339

Study #:
STUDY00141828

Start Date:
Feb 19, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03303339

View Complete Trial Details & Eligibility at ClinicalTrials.gov